Basic research of immunotherapy using dendritic cells derived from induced pluripotent stem cells in healthy donors and cancer patients

Basic research of immunotherapy using dendritic cells derived from induced pluripotent stem cells in healthy donors and cancer patients - Basic research of immunotherapy using dendritic cells derived from induced pluripotent stem cells in healthy donors and cancer patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021105

Enrollment

Registered

2016-03-01

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent gastrointestinal cancer

Interventions

Collection of blood sample up to 50ml Sampling cancer tissue from cancer patients within the necessary to treat the patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Advanced or recurrent gastrointestinal cancer confirmed adenocarcinoma or squamous cell carcinoma 2)Over clinical StageIII in UICC-TNM 3)Aged from 20 to 75 years 4)Performance status 0 or 1 5)Patient who has never had chemotherapy, radiation therapy, and endocrine therapy for cancer 6)Sufficient functions of major organ 7)Full filling the following conditions within 2 weeks before registration WBC from 4,000/mm3 to 12,000/mm3. Neutrophils over 2,000/mm3. Hemoglobin over 8.0g/dL. Plate over 100,000/mm3. AST under 100IU/L, or ALT under 100IU/L. Total bilirubin under 1.5mg/dL. Serum creatinine under 1.2mg/dL. Creatinine clearance over 60mL/min/body. 8)Having written informed consent

Exclusion criteria

Exclusion criteria: 1)Active other malignancy, except lesions of "carcinoma in situ" or intramucosal location which are curatively resectable 2)Pregnant or lactating woman 3)Sever mental impairment 4)Active or uncontrolled clinically serious infection, except local infection not influencing general status 5)Judged inappropriate by the investigators

Design outcomes

Primary

Measure	Time frame
To investigate the capacity of the DCs derived from iPS cells in healthy donors and cancer patients to prime TAA-specific CTLs comparatively with the DCs derived from peripheral blood mononuclear cells (PBMCs) in the donors and the patients	—

Secondary

Measure	Time frame
To investigate the morphology of the DCs derived from iPS cells in healthy donors and cancer patients comparatively with the DCs derived from PBMCs in the donors and the patients To investigate the capacity in terms of maturation and migration of the DCs derived from iPS cells in healthy donors and cancer patients comparatively with the DCs derived from PBMCs in the donors and the patients To verify the expression of tumor associated antigen in cancer cells sampled from cancer patients	—

Measure

Time frame

To investigate the morphology of the DCs derived from iPS cells in healthy donors and cancer patients comparatively with the DCs derived from PBMCs in the donors and the patients To investigate the capacity in terms of maturation and migration of the DCs derived from iPS cells in healthy donors and cancer patients comparatively with the DCs derived from PBMCs in the donors and the patients To verify the expression of tumor associated antigen in cancer cells sampled from cancer patients

—

Countries

Japan

Contacts

Public ContactHirotaka Tabata

Wakayama Medical University Second Department of Surgery

htabata@wakayama-med.ac.jp073-441-0613

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026